ZYBERNO
Stock Report
Updated Jun 4, 2026

THIRD HARMONIC BIO, INC. (THRD)

Healthcare • NASDAQ

$5.39

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
THIRD HARMONIC BIO, INC. (THRD) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-19.3%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.02x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,239.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

THIRD HARMONIC BIO, INC. (THRD) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, THRD generated -$41.70M in Owner Earnings. Capital was deployed as follows: $10.00K invested in capital expenditures. Reinvestment rate: 0.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:5.39
Market Cap:$242.10M

Valuation Multiples (3)

P/B Ratio:0.89x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$26.51M
B. Profitability Assessment

Return Metrics (5)

ROA:-18.7%
Reinvestment Rate:0.1%
Fundamental Growth Rate (g):-1.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:$23.01
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:54.10x
Quick Ratio:54.10x
Cash Ratio:53.24x

Leverage Analysis (3)

Debt To Equity Ttm:0.02x
Debt-to-Equity Ratio:0.02x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-4.58x
Times Interest Earned:-4.58

Capital Structure (4)

Working Capital:270,895,000.00
Cash And Cash Equivalents:271,611,000.00
Long Term Debt:$2.11M
Net Debt:-$268.61M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$66.30M

Bottom Line Performance (3)

-$53.45M
Income Before Tax:-$45.47M
Ebitda Ttm:-66,248,000.00

Operating Expenses (5)

Operating Expenses:66,298,000.00
R And D Expense:40,919,000.00
Sga Expense:25,379,000.00
Income Tax Expense:$0.00
Interest Expense:12,864,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$279.84M
Current Assets:$276.00M
Ppe Net:117,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:7,215,000.00
Current Liabilities:5,102,000.00
Long Term Debt:$2.11M
Short Term Debt:$889.00K

Equity & Capital (3)

Equity:$272.62M
Retained Earnings:-$175.52M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:2,683,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:3,270,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$41.69M-$41.70M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:10,000.00

Financing Activities (3)

Financing Cash Flow:$35.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:48,668,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:50,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):1.24
Eps diluted TTM: $1.24
Linear Growth: 22.4%
📊 Click to view full THRD EPS analysis & methodology →
Earnings Per Share Ttm:-$1.19

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.77

Book Value & Capital (2)

Book Value Per Share:$6.07
Cash Per Share:6.05

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$41.70M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.1%
Fundamental Growth Rate (g):-1.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-1.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:THRD
Company Name:THIRD HARMONIC BIO, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:44.92M
Shares Outstanding Basic:44.92M
Shares Outstanding Diluted:44.92M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-04 14:46:38 UTC
Data Timestamp:2026-06-04T14:46:38.919921
Scroll to Top